Figure 4: CSN5i-3 inhibits tumour growth of a human xenograft.
From: Targeted inhibition of the COP9 signalosome for treatment of cancer
(a) SU-DHL-1 xenografts were grown in SCID-bg mice and dosed by oral administration with either vehicle control or CSN5i-3 at the indicated doses and schedules. Mean tumour volumes are shown±s.e.m. (n=4; P<0.05). (b) Immunoblotting for Cul1 and Skp2 of tumours excised at the end of treatment. (c) Pharmacokinetics of CSN5i-3 post second to last dose. Mean blood concentrations are shown±s.e.m. (n=4).
